Robert Chapman
Impact in
- Molecular Medicine top 1%
- Curcumin's Biomedical Applications
- Geriatrics and Gerontology top 2%
- Sirtuins and Resveratrol in Medicine
Papers in
- Oncology 47
- Lung Cancer Research Studies 16
- Global Cancer Incidence and Screening 8
- Cancer Treatment and Pharmacology 6
- Co-authors
- Subhash C. GautamXiaohua GaoNalini JanakiramanYong XuGeorge DivineDorrah DeebHao JiangTerrance L. Albrecht
- Journals
- Journal of Clinical Oncology (10 papers)Cancer (7 papers)Investigational New Drugs (7 papers)Journal of Thoracic Oncology (5 papers)Biochemical Pharmacology (4 papers)
- Partner nations
- United StatesCanadaAustralia
In The Last Decade
Robert Chapman
92 papers receiving 3.4k citations
Hit Papers
Peers
Comparison fields: 5 of 152
- Molecular Medicine 434
- Geriatrics and Gerontology 208
- Oncology 1.1k
- Hematology 407
- Pulmonary and Respiratory Medicine 754
Countries citing papers authored by Robert Chapman
This map shows the geographic impact of Robert Chapman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Chapman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Chapman more than expected).
Fields of papers citing papers by Robert Chapman
This network shows the impact of papers produced by Robert Chapman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Chapman. The network helps show where Robert Chapman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Robert Chapman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 32 | |
| 2 | 2016 | 60 | |
| 3 | 2013 | 12 | |
| 4 | 2012 | 1 | |
| 5 | 2008 | 116 | |
| 6 | 2008 | 63 | |
| 7 | 2007 | 2 | |
| 8 | 2007 | 42 | |
| 9 | 2006 | 20 | |
| 10 | 2003 | 3 | |
| 11 | 2003 | 58 | |
| 12 | 2000 | 12 | |
| 13 | 2000 | 10 | |
| 14 | 1999 | 3 | |
| 15 | 1998 | 6 | |
| 16 | 1998 | 20 | |
| 17 | 1997 | 45 | |
| 18 | 1993 | 8 | |
| 19 | 1991 | 4 | |
| 20 | Phase II trials of methylglyoxal bis (guanylhydrazone) (MGBG) in 3 solid tumors | 1981 | 2 |
About Robert Chapman
Robert Chapman is a scholar working on Oncology, Molecular Medicine, Pulmonary and Respiratory Medicine, Geriatrics and Gerontology and Pathology and Forensic Medicine, having authored 93 papers that have together received 3.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (16 papers), Global Cancer Incidence and Screening (8 papers), Lymphoma Diagnosis and Treatment (8 papers), Lung Cancer Diagnosis and Treatment (7 papers), Neuroendocrine Tumor Research Advances (6 papers), Patient-Provider Communication in Healthcare (6 papers) and Cancer Treatment and Pharmacology (6 papers). The work is most often cited by research in Molecular Medicine (434 citations), Geriatrics and Gerontology (208 citations), Oncology (1.1k citations), Hematology (407 citations) and Pulmonary and Respiratory Medicine (754 citations). Robert Chapman has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Subhash C. Gautam, Xiaohua Gao, Nalini Janakiraman, Yong Xu, George Divine, Dorrah Deeb, Hao Jiang, Terrance L. Albrecht, Susan Eggly and Louis A. Penner. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Investigational New Drugs, Journal of Thoracic Oncology and Biochemical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.